Cognivue, Inc. Joins Milken Institute’s Alliance to Improve Dementia Care Steering Committee
The Alliance seeks to transform and improve the complex health and long-term care systems for individuals at risk for and living with dementia.
ROCHESTER, N.Y., June 9, 2021—Neuroscience company Cognivue, Inc. today announced that its President and CEO, Tom O’Neill, has joined the Milken Institute’s Alliance to Improve Dementia Care Steering Committee. The Milken Institute Center for the Future of Aging launched the Alliance to Improve Dementia Care in July 2020 to engage public, private, and nonprofit sector decision makers, advance comprehensive dementia-care and payment models, and build a dementia-capable system and workforce.
“Early detection of cognitive impairment is critically important in order for patients to make timely decisions to manage their condition. Cognivue’s technology objectively, quantitatively, and reliably identifies cognitive status and can elevate the standard of care for cognitive health assessment and treatment,” said Tom O’Neill, president and CEO of Cognivue. “This is an encouraging time in terms of research and development efforts, and it is an honor to be a part of the Alliance’s efforts to improve the way dementia is detected and diagnosed and care is delivered.”
Cognivue joins Alliance members AARP, Bank of America, Biogen, Humana, The John A. Hartford Foundation and other respected biopharma, healthcare, and research entities. The company’s technologies, including the first FDA-cleared computerized test of cognitive function, are designed to provide healthcare providers a useful tool for cognitive evaluation and diagnosis of various neurodegenerative and neuropsychological disorders. The digital system is engineered to eliminate bias and variability throughout the test that establish cognitive baselines and provide a concurrent monitoring vehicle for the evaluation and treatment of cognitive issues over time.
“The Alliance to Improve Dementia Care welcomes Cognivue and its knowledge and expertise as we work toward our goals of advancing recommendations to identify gaps in, and improve, brain health and dementia care,” said Nora Super, executive director, Alliance to Improve Dementia Care and senior director, Milken Institute Center for the Future of Aging.
About Cognivue, Inc.
Cognivue, Inc. is a world-class neuroscience company focusing on cognitive health with the world’s first FDA-cleared computerized test of cognitive function. The Cognivue device and technology are based on years of research that uses adaptive psychophysics to focus on cortical information processing by testing key cognitive domains. The technology significantly improves the ability of healthcare providers to implement a personalized assessment of cognitive function in a wide variety of care settings. The company is elevating the gold standard of cognitive health assessment and empowering the healthcare community to monitor, identify and act on early detection of cognitive health concerns. For more information, call 585-203-1969 or visit cognivue.com.
About the Milken Institute Alliance to Improve Dementia Care
The Milken Institute is a nonprofit, nonpartisan think tank and its Alliance to Improve Dementia Care brings together a multi-sector coalition of leaders to advance timely detection, access to treatment and coordinated care, and health equity for people at risk of and living with dementia and their caregivers. Through expert workgroups, convenings, and collaborative initiatives, the Alliance amplifies and promotes the adoption of proven solutions and promising innovations.
For Cognivue, Inc.
Christopher Knospe, email@example.com, +1 (585) 434-2154